These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11360239)

  • 1. Construction of Oka varicella vaccine expressing human immunodeficiency virus env antigen.
    Shiraki K; Sato H; Yoshida Y; Yamamura JI; Tsurita M; Kurokawa M; Kageyama S
    J Med Virol; 2001 Jun; 64(2):89-95. PubMed ID: 11360239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of immunogenic recombinant Oka varicella vaccine expressing hepatitis B virus surface antigen.
    Shiraki K; Hayakawa Y; Mori H; Namazue J; Takamizawa A; Yoshida I; Yamanishi K; Takahashi M
    J Gen Virol; 1991 Jun; 72 ( Pt 6)():1393-9. PubMed ID: 1646279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of humoral and cell-mediated immunity to hepatitis B surface antigen by a novel adjuvant activity of Oka varicella vaccine.
    Phumiamorn S; Sato H; Kamiyama T; Kurokawa M; Shiraki K
    J Gen Virol; 2003 Feb; 84(Pt 2):287-291. PubMed ID: 12560559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A recombinant varicella vaccine harboring a respiratory syncytial virus gene induces humoral immunity.
    Murakami K; Matsuura M; Ota M; Gomi Y; Yamanishi K; Mori Y
    Vaccine; 2015 Nov; 33(45):6085-92. PubMed ID: 26116253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of a recombinant Oka varicella vaccine expressing mumps virus hemagglutinin-neuraminidase protein as a polyvalent live vaccine.
    Somboonthum P; Yoshii H; Okamoto S; Koike M; Gomi Y; Uchiyama Y; Takahashi M; Yamanishi K; Mori Y
    Vaccine; 2007 Dec; 25(52):8741-55. PubMed ID: 18053621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune response to varicella-zoster virus glycoproteins in guinea pigs infected with Oka varicella vaccine.
    Sato H; Kageyama S; Imakita M; Ida M; Yamamura J; Kurokawa M; Shiraki K
    Vaccine; 1998 Aug; 16(13):1263-9. PubMed ID: 9682389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of glycoprotein E subunit and live attenuated varicella-zoster virus vaccines formulated with a single-strand RNA-based adjuvant.
    Lee SJ; Park HJ; Ko HL; Lee JE; Lee HJ; Kim H; Nam JH
    Immun Inflamm Dis; 2020 Jun; 8(2):216-227. PubMed ID: 32167678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel immunogenicity of Oka varicella vaccine vector expressing hepatitis B surface antigen.
    Kamiyama T; Sato H; Takahara T; Kageyama S; Shiraki K
    J Infect Dis; 2000 Mar; 181(3):1158-61. PubMed ID: 10720546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recombinant Oka varicella vaccine as a live hepatitis B virus vaccine].
    Shiraki K; Takahara T
    Nihon Rinsho; 1993 Jan; 51(1):241-7. PubMed ID: 8381884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs.
    Heineman TC; Connelly BL; Bourne N; Stanberry LR; Cohen J
    J Virol; 1995 Dec; 69(12):8109-13. PubMed ID: 7494331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant simian varicella viruses induce immune responses to simian immunodeficiency virus (SIV) antigens in immunized vervet monkeys.
    Ou Y; Traina-Dorge V; Davis KA; Gray WL
    Virology; 2007 Aug; 364(2):291-300. PubMed ID: 17434552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the hepatitis B surface antigen.
    Fomsgaard A; Nielsen HV; Bryder K; Nielsen C; Machuca R; Bruun L; Hansen J; Buus S
    Scand J Immunol; 1998 Apr; 47(4):289-95. PubMed ID: 9600309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
    J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content.
    Bergen RE; Diaz PS; Arvin AM
    J Infect Dis; 1990 Nov; 162(5):1049-54. PubMed ID: 2172393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen.
    Vijayan A; García-Arriaza J; Raman SC; Conesa JJ; Chichón FJ; Santiago C; Sorzano CÓ; Carrascosa JL; Esteban M
    PLoS One; 2015; 10(7):e0133595. PubMed ID: 26208356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A human immunodeficiency virus type 1 Env-granulocyte-macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine.
    Rodr Guez D; Rodr Guez JR; Llorente M; V Zquez I; Lucas P; Esteban M; Mart Nez-A C; Del Real G
    J Gen Virol; 1999 Jan; 80 ( Pt 1)():217-223. PubMed ID: 9934705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical application of HIV DNA vaccine with cytokine-expression plasmids induces strong antigen-specific immune responses.
    Liu LJ; Watabe S; Yang J; Hamajima K; Ishii N; Hagiwara E; Onari K; Xin KQ; Okuda K
    Vaccine; 2001 Oct; 20(1-2):42-8. PubMed ID: 11567744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.